Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

MLA

Diana Abbott, et al. “Venetoclax and Azacitidine Compared with Induction Chemotherapy for Newly Diagnosed Patients with Acute Myeloid Leukemia.” Blood Advances, vol. 5, no. 24, Dec. 2021, pp. 5565–73. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7bb69e6a71c81d1193956adeda8126cc&authtype=sso&custid=ns315887.

APA

Diana Abbott, Clayton A. Smith, Julie Rosser, Mohd Minhajuddin, Maria L. Amaya, Jeffrey Schowinsky, Daniel A. Pollyea, Anagha Inguva, Craig T. Jordan, Amanda Winters, Christine McMahon, Jonathan A. Gutman, Audrey Sato, Evan Cherry, Marc Schwartz, Shanshan Pei, & Brett M. Stevens. (2021). Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Advances, 5(24), 5565–5573.

Chicago

Diana Abbott, Clayton A. Smith, Julie Rosser, Mohd Minhajuddin, Maria L. Amaya, Jeffrey Schowinsky, Daniel A. Pollyea, et al. 2021. “Venetoclax and Azacitidine Compared with Induction Chemotherapy for Newly Diagnosed Patients with Acute Myeloid Leukemia.” Blood Advances 5 (24): 5565–73. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7bb69e6a71c81d1193956adeda8126cc&authtype=sso&custid=ns315887.